ライフサイエンスコーパス: cystatin C

1 ment (R(2) = 0.989 for CRP; R(2) = 0.939 for cystatin C).

2 markers of filtration (serum creatinine and cystatin C).

3 l, 0.8-4.1] per standard deviation change in cystatin C).

4 explaining 2.8% of the observed variation in cystatin C.

5 on rate (eGFR) based on serum creatinine and cystatin C.

6 data for amyloids from either cystatin B or cystatin C.

7 rer prognosis within cohorts of high and low cystatin C.

8 cells (DC) are the predominant producers of cystatin C.

9 established renal function indices eGFR and cystatin C.

10 rmined by longitudinal measurements of serum cystatin C.

11 tory activity or amyloidogenic properties of cystatin C.

12 atinine, cystatin C (eGFRcys) and creatinine-cystatin C.

13 ar filtration rate (GFR), estimated GFR, and cystatin C.

14 a traditional sandwich immunoassay for serum cystatin C.

15 han when cells were incubated with wild-type cystatin C.

16 rovement in reclassification with the use of cystatin C.

17 s illustrated by incubating cells with W106F-cystatin C.

18 We estimated GFR using cystatin C.

19 inine, 24% did not have CKD by either ACR or cystatin C.

20 inine, 3863 (16%) had CKD detected by ACR or cystatin C.

21 to creatinine-based equations compared with cystatin C.

22 for legumain is 100-fold higher than that of cystatin C.

23 terminal pro-B type natriuretic peptide, and cystatin C.

24 ylarginine, high-sensitivity troponin T, and cystatin C.

25 equation based on both plasma creatinine and cystatin C.

26 are never labelled with anti-TDP-43 or anti-cystatin C.

27 proteinuria, and a 6-fold increase in serum cystatin-C.

28 ctive treatment's effect and EF on change in cystatin-C.

29 tin vs placebo; P = .033) and decreased mean cystatin C (-0.034 mg/L vs 0.010 mg/L; P = .008).

30 ive protein -0.0363 (95% CI 0.0601--0.0124), cystatin C -0.0391 (95% CI -0.0772--0.00107).

31 ct to limits of detection (CRP, 0.10 mug/mL; cystatin C, 0.003 mug/mL) and coefficients of variation

32 he extracellular cysteine protease inhibitor cystatin C, 12 variants of the protein were produced and

33 nd coefficients of variation (CRP, 2.4-7.0%; cystatin C, 3.0-8.9%).

34 rs911119 was associated with decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p =

35 l relative risk for CVD of 1.00 per doubling cystatin C (95% CI: 0.82 to 1.22; p = 0.994), which was

36 factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence interval [CI]: 1.56 to 2.13;

37 alysis, we examined the relationship between cystatin C (a marker of renal function) and PASP and pot

38 al serum potassium levels and measurement of cystatin C, a non-creatinine measure of kidney function.

39 ning isogenic cells homozygous for variant B cystatin C, a recessive risk factor for age-related macu

40 All cells internalized cystatin C added to culture media, leading to increased

41 , we developed estimating equations based on cystatin C alone and in combination with creatinine in d

42 The use of cystatin C alone or in combination with creatinine stren

43 lculated by the measurement of creatinine or cystatin C alone or in combination with creatinine, with

44 .9-2.7) for participants with CKD defined by cystatin C alone, and 3.0 (95% CI, 2.4-3.7) for particip

45 etter than equations that used creatinine or cystatin C alone.

46 ptide]), there was a significant increase in cystatin C among patients randomized to liraglutide rais

47 e offspring, suggesting the presence of L68Q cystatin C amyloid affected sperm function.

48 Hereditary cystatin C amyloid angiopathy is an autosomal dominant d

49 L68Q protein deposits in human cystatin C amyloid angiopathy patients have also been fo

50 In hereditary cystatin C amyloid angiopathy, a cystatin C variant is d

51 d causes a fatal amyloid disease, hereditary cystatin C amyloid angiopathy.

52 howed increased levels and distinct forms of cystatin C amyloid that were not present in WT mice.

53 Cystatin C amyloids cause a hereditary form of cerebral

54 L68Q epididymal fluid that was depleted of cystatin C amyloids, however, did not impair the motilit

55 cohorts (n = 76,481) with 37,126 measures of cystatin C and added genetic data from 43 studies (n = 2

56 Higher cystatin C and beta trace protein associated with a high

57 m underlying the strong relationship between cystatin C and cardiovascular risk.

58 ult ICU survivors, we compared ICU discharge cystatin C and creatinine and their association with 1-y

59 During ICU admission, serum cystatin C and creatinine diverged, so that by ICU disch

60 ge in the C statistic was noted with FRSVs + cystatin C and FRSVs + creatinine compared with FRSVs al

61 d to determine the association between serum cystatin C and mortality.

62 espectively, of the indirect effects between cystatin C and PASP.

63 Rosuvastatin 10 mg daily reduces plasma cystatin C and slows kidney function decline in HIV-infe

64 highly ordered, domain-swapped assemblies of cystatin C and that the oligomers could not build larger

65 This, along with the rise of serum cystatin C and the reduced inulin and creatinine clearan

66 Here we aimed to investigate if uptake of cystatin C and the related inhibitor cystatin E/M occur

67 we evaluate endogenous cathepsin inhibitors cystatins C and B.

68 ssociations of eGFR (based on creatinine and cystatin C) and ACR with cancer risk using Cox regressio

69 y cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and ala

70 for those with CKD defined by creatinine and cystatin C, and 5.6 (95% CI, 3.9-8.2) for those with CKD

71 od gas, inflammatory cytokine concentration, cystatin C, and alanine aminotransferase.

72 er adjustment for GFR, levels of creatinine, cystatin C, and beta trace protein, each remained direct

73 immunosorption, using immobilized monomeric cystatin C, and elution from columns with immobilized cy

74 -stratified models with FRSVs alone, FRSVs + cystatin C, and FRSVs + creatinine.

75 Four markers (albumin, beta-2-microglobulin, cystatin C, and osteopontin) were undetectable in most A

76 many solutes, including carboxymethyllysine, cystatin C, and parathyroid hormone.

77 isease Epidemiology Collaboration creatinine-cystatin C, and urate and high-sensitivity C-reactive pr

78 with increased aortic pulsed wave velocity, cystatin C, and urinary albumin-to-creatinine ratio.

79 nalyzed by levels of serum creatinine, urea, cystatin-C, and urea creatinine.

80 nogen, C-reactive protein, sST2, galectin-3, cystatin-C, and urinary albumin-to-creatinine ratio.

81 Conversely, lower creatinine relative to cystatin C appeared to confer adverse prognosis, confoun

82 herapeutics targeted at lowering circulating cystatin C are unlikely to be effective in preventing CV

83 implications for the diagnostic use of serum cystatin C as a marker of kidney function during inflamm

84 isual readout and applied it to an assay for cystatin C as a model target.

85 fication improvement with the measurement of cystatin C, as compared with creatinine, was 0.23 (95% c

86 FR to a higher value with the measurement of cystatin C, as compared with creatinine, was associated

87 igher than SCr (AUC-ROC=0.73) and similar to cystatin C (AUC-ROC=0.91).

88 accuracy and lowest error were observed with cystatin C-based chronic kidney disease epidemiology col

89 mination of renal function by creatinine and cystatin C-based eGFR revealed decreasing eGFRs in the d

90 (2) of body-surface area was higher with the cystatin C-based eGFR than with the creatinine-based eGF

91 s were consistent for creatinine-based eGFR, cystatin C-based eGFR, and UACR.

92 tly associated with childhood kidney volume, cystatin C-based eGFR, or the risk of microalbuminuria.

93 Kidney function was measured by cystatin C-based estimated glomerular filtration rate (e

94 3.51) in models adjusted for age, sex, race, cystatin C-based estimated glomerular filtration rate, b

95 Creatinine- but not cystatin C-based estimations largely derived over ICU st

96 One of 3 CKD stages diagnosed by cystatin c-based formulas was incorrect, with both overe

97 We compared 51 creatinine-based and/or cystatin c-based formulas with a gold standard (iohexol

98 e-based formulas: approximately 0.70 and for cystatin c-based formulas: approximately 0.85).

99 012) was superior to previous creatinine- or cystatin C-based GFR equations.

100 , and previously reported creatinine- and/or cystatin C-based GFR-estimating equations.

101 We estimated cystatin C-based glomerular filtration rate (eGFR(cys))

102 lable creatinine at baseline (n=17 951), and cystatin C-based glomerular filtration rate was estimate

103 our knowledge, no previous studies have used cystatin C-based measures of the estimated glomerular fi

104 lomerular filtration rate with creatinine or cystatin C-based standard and kinetic equations as well

105 IS1: creatinine-based; BIS2: creatinine- and cystatin C-based) with other estimating equations and de

106 0% (creatinine-based) and approximately 50% (cystatin c-based), indicating that 90% of the estimation

107 We further assessed the impact of using cystatin-C-based eGFR in risk prediction equations for C

108 and international guidelines recommend that cystatin-C-based estimates of GFR be used to confirm or

109 Whilst there is good evidence for cystatin C being a marker of GFR and risk in people with

110 nt variable for kidney function (creatinine, cystatin C, beta2-microglobulin).

111 sC5b-9) and renal injury markers (clusterin, cystatin-C, beta2-microglobulin, and liver fatty acid bi

112 red childhood kidney volumes, creatinine and cystatin C blood levels, microalbuminuria, BP, and eGFR.

113 Statins may improve cystatin C by improving glomerular function or by decrea

114 Serum cystatin C, by itself or as a part of an estimated GFR,

115 m2, calculated using the combined creatinine-cystatin C CKD-Epidemiology Collaboration Equation.

116 omarkers (haemoglobin, cTn-hs, and GDF-15 or cystatin C/CKD-EPI) was internally and externally valida

117 ss than 60 mL/min/1.73 m when estimated from cystatin C compared with glomerular filtration rate esti

118 baseline and 0- to 24-week changes in plasma cystatin C concentration with measures of vascular disea

119 CIAKI (ie, an increase >10% of serum cystatin C concentration within 24 hours after CM exposu

120 Cystatin C concentrations remained normal in both groups

121 Cystatin C concentrations were associated with CVD risk

122 ation rate (eGFR) using serum creatinine and cystatin C concentrations, and microalbuminuria using ur

123 In contrast to creatinine, cystatin C consistently associated with long-term mortal

124 Within the statin group, changes in cystatin C correlated with changes in endothelial activa

125 gh-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-sensitivity C-reactive protein

126 We investigated whether cystatin C (CysC) and neutrophil gelatinase-associated l

127 tion rate (GFR) equations incorporating both cystatin C (CysC) and serum creatinine (Creat) in living

128 Cr is a commonly accepted clinical standard, cystatin C (CysC) has shown superiority in assessment of

129 Cystatin C (CysC) is a better glomerular filtration rate

130 Cystatin C (CysC) is a versatile and ubiquitously-expres

131 Cystatin C (CysC) is an early biomarker of renal dysfunc

132 Cystatin C (CysC) is implicated in neuroprotection and r

133 t renal function measures are imperfect, and cystatin C (CysC) is promoted as a better marker of glom

134 Of note, circulating cystatin C (CysC) levels were increased in UniNx compare

135 ent redox activity mediated by ferrocene for Cystatin C (CysC), an early kidney failure biomarker, is

136 tB is inhibited by its endogenous inhibitor, cystatin C (CysC).

137 ating fragments but is potently inhibited by cystatin C (CysC).

138 Serum cystatin C (CysC; subdistribution hazard ratio [SHR], 1.

139 the legumain binding region (N39K- and N39A-cystatin C) decreased the internalization and (R24A,R25A

140 1 promotes fibrosis by driving the effective cystatin C-dependent inhibition of extracellular matrix-

141 ) in young and middle-aged adults who have a cystatin C-derived estimated glomerular filtration rate

142 D) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate

143 measurement method of renal function such as cystatin-C-derived or directly measured GFR.

144 e intracellular concentration of ROS inhibit cystatin C dimerization.

145 These could be used to selectively remove cystatin C dimers from biological fluids containing both

146 s, and of the potential legumain inhibitors, cystatin C, E/M, and F, cystatin C was the one mainly pr

147 es/mL was associated with a lower creatinine/cystatin C eGFR at 2 years post-HCT.

148 es/mL was associated with a lower creatinine/cystatin C eGFR two years post-HCT.

149 ed GFR estimated from creatinine (eGFR(Cr)), cystatin C (eGFR(Cys)), or both (eGFR(Cr+Cys)) with ioth

150 ion rate estimated from serum creatinine and cystatin C (eGFR) from baseline to year 5.

151 reatinine (eGFR_Cr), and eGFR estimated from cystatin C (eGFR_cysC).

152 e Epidemiology Collaboration eGFR creatinine-cystatin C (eGFRcreat-cys) equation.

153 eGFR by cystatin C (eGFRcys) and albumin-to-creatinine ratio wer

154 We estimated GFR using both cystatin C (eGFRcys) and creatinine (eGFRcreat).

155 eGFR was calculated using serum creatinine, cystatin C (eGFRcys) and creatinine-cystatin C.

156 GFR should be calculated and reported using cystatin C (eGFRcys) and serum creatinine (eGFRcr-cys) o

157 d GFR estimated from creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys) at baseli

158 diagnostic performance of CKD-EPI creatinine-cystatin C equation (2012) in patients with cirrhosis wa

159 Performance of the new CKD-EPI creatinine-cystatin C equation (2012) was superior to previous crea

160 73 m(2) with the creatinine equation and the cystatin C equation (P=0.07 and P=0.05), respectively.

161 r the BIS2 equation (11.6%), followed by the cystatin C equation 2 (15.1%) proposed by the Chronic Ki

162 Accuracy of CKD-EPI creatinine-cystatin C equation as quantified by root mean squared e

163 ubjects, GFR estimated by CKD-EPI creatinine-cystatin C equation differed from the mGFR by more than

164 te the performance of the CKD-EPI creatinine-cystatin C equation in subjects with cirrhosis, we compa

165 The combined creatinine-cystatin C equation performed better than equations base

166 In the validation data set, the creatinine-cystatin C equation performed better than equations that

167 and "accuracy" of the new CKD-EPI creatinine-cystatin C equation to that of 24-hour urinary creatinin

168 Cystatin C forms non-inhibitory dimers and aggregates by

169 ongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function e

170 Furthermore, immunodepletion of cystatin C from the conditioned medium completely remove

171 Vimentin, cystatin C, galectin-1, IGFBP-7, and secreted protein, a

172 y C-reactive protein greater than 3.0 mg/dL, cystatin C >/=1.11 mg/dL, estimated glomerular filtratio

173 lomerular filtration rate, or an increase in cystatin C >=0.3 mg/L from baseline to 180-days.

174 tive protein, urinary albumin excretion, and cystatin-C had similar risk for new-onset HF between bot

175 Serum cystatin C has an important role in enhancing accuracy o

176 from serum concentrations of creatinine and cystatin C has been refined using cross-sectional data f

177 ne the extent to which the addition of serum cystatin C improves glomerular filtration rate (GFR) est

178 vation and inflammation were associated with cystatin C in a multivariable model independent of creat

179 Cystatin C in combination with [TIMP-2] x [IGFBP7] 24 ho

180 l variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, isc

181 s 6.4% (P < .001) after adding estimated GFR cystatin C in fully adjusted models with estimated GFR c

182 (from 0.64 (49 nM) to 0.96 mg/L (74 nM)) of cystatin C in serum.

183 on analyses did not support a causal role of cystatin C in the etiology of CVD.

184 cell types synthesize monomeric and dimeric cystatin C in vivo, but only secrete monomer.

185 ulative urine volume and the change in serum cystatin-C in 72 hours.

186 t and confirmed an increased uptake of W106F-cystatin C, in PC3 cells.

187 of GFR-estimating equations with and without cystatin C, including the modification of diet in renal

188 ile serum creatinine fell at 12 hours, serum cystatin C increased, suggestive of decreased creatinine

189 , galectin-3, midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.

190 prostate cancer cells corroborated that the cystatin C internalization is generally relevant and con

191 Cystatin C is an alternative filtration marker for estim

192 iological studies show that high circulating cystatin C is associated with risk of cardiovascular dis

193 ndelian randomization to investigate whether cystatin C is causally related to CVD in the general pop

194 The cysteine protease inhibitor cystatin C is internalized by some cancer cells, which a

195 Low extracellular cystatin C is linked to pathologic protease activity in

196 If cystatin C is not available, the BIS1 equation is an acc

197 The cysteine protease inhibitor cystatin C is thought to be secreted by most cells and e

198 he extracellular concentration of inhibitory cystatin C is thus partly dependent on the abundance of

199 Relationships between cystatin C, kidney function, and cardiovascular risk in

200 dominant disorder in which a variant form of cystatin C (L68Q) readily forms amyloid deposits in cere

201 714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18

202 618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.

203 ely associated with childhood creatinine and cystatin C levels (all P values <0.05), but did not asso

204 re media, leading to increased intracellular cystatin C levels by 120-200%.

205 ells are major contributors to extracellular cystatin C levels in healthy mice.

206 filtration rate (GFR) was estimated based on cystatin C levels using the relevant equation.

207 stimated glomerular filtration rate based on cystatin C levels using the relevant equation.

208 ated on the basis of creatinine (eGFRcr) and cystatin C levels were assessed in </=1735 participants

209 gression models showed that age and baseline cystatin C levels were associated with WRF.

210 Cystatin C levels were positively and plasma high-densit

211 After adjustment for both creatinine and cystatin C levels, higher discharge creatinine was then

212 easured GFR from standardized creatinine and cystatin C levels, sex, and age in the learning sample;

213 ut cirrhosis using both serum creatinine and cystatin C levels.

214 -treated groups had a 35% reduction in serum cystatin-C levels and reduced crescent numbers compared

215 allel with Elmo1, as do the plasma levels of cystatin C, lipid peroxides, and TGFbeta1, and erythrocy

216 munodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glome

217 imilarly, both in patients with high and low cystatin C (median cut-off), higher plasma NGAL levels w

218 ed GFR, the formula with both creatinine and cystatin C, namely, CKD-epidemiology cr-cys, outperforme

219 phosphatase, gamma-glutamyl transpeptidase, cystatin C, neutrophil gelatinase-associated lipocalin,

220 Except for a modest effect of cystatin-C, no biomarker was associated with increased r

221 between logged and standardized measures of cystatin C, NT-proBNP (N-terminal pro-B-type natriuretic

222 Cystatin C, NT-proBNP, and IL-6 (but not E-selectin) wer

223 n rate (GFR) determined by creatinine and by cystatin C of either <60 or >/=60 mL/min/1.73 m(2) and A

224 C, and elution from columns with immobilized cystatin C oligomers, oligomer-specific antibodies were

225 .002), and GFR-estimating equations based on cystatin C only.

226 In models including either cystatin C or beta trace protein, the association of GFR

227 all and not significant with the addition of cystatin C or creatinine to FRSVs.

228 tudied the incremental value of adding serum cystatin C or creatinine to the Framingham risk score va

229 In contrast, cystatin C or high-sensitivity C-reactive protein did no

230 In conclusion, the addition of cystatin C or serum creatinine to FRSVs does not improve

231 Serum levels of creatinine, cystatin C, or beta trace protein allow estimation of GF

232 lternative biomarkers (haematocrit, cTnI-hs, cystatin C, or creatinine clearance) also outperformed t

233 not increase albuminuria, proteinuria, serum cystatin C, or serum creatinine levels in TxNIP(-/-) mic

234 plasma biomarkers of renal injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloprot

235 = .026, area under ROC curve [AUC] = 0.818), cystatin C (P = .033, AUC = 0.805), and creatinine (P =

236 le risk prediction model, eGFR (P=0.616) and cystatin C (P=0.937) were no longer associated with mort

237 In addition, cystatin C participated in the control of extracellular

238 bining a functional damage biomarker (plasma cystatin C [pCysC]) with a tubular damage biomarker (uri

239 8.30-21.2); Pnoninferiority = 0.0011], serum cystatin C (Pnoninferiority < 0.0001), serum creatinine

240 ons, little is known about the regulation of cystatin C production, dimerization, and secretion.

241 of cystatin C under the control of the mouse cystatin C promoter were unable to generate offspring, s

242 n decline of eGFR (Ptrend<0.001) and rise of cystatin C (Ptrend=0.01) and creatinine (Ptrend<0.001) l

243 mo Diet and Cancer study (MDC) into baseline cystatin C quintiles (n=4757).

244 atinine measure but detected by both ACR and cystatin C (rate per 1000 person-years, 6.4; 95% CI, 3.6

245 ation coefficient, serum creatinine-to-serum cystatin C ratio was found to be the best performer in t

246 ient increase in serum creatinine, but serum cystatin C remained stable.

247 ly by iothalamate and creatinine (eGFRcr) or cystatin C, respectively.

248 renal function, C-reactive protein (CRP) and cystatin C, respectively.

249 ith increases in endothelin-1 and creatinine/cystatin C, respectively.

250 combination of newly tested biomarkers with cystatin C resulted in a significantly improved diagnost

251 he control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vitamin K-Dependent Protein S[

252 The role of serum cystatin C (Scyc), neutrophil gelatinase-associated lipo

253 t this effect is mediated via an increase in cystatin C secretion.

254 beta trace protein and cystatin C seem to provide more consistent prognostic in

255 ss or diet), or interference with the assay, cystatin C should be measured and estimated GFR should b

256 Two variants, W106F- and K75A-cystatin C, showed that the internalization can be posit

257 ation, we use redox experiments of monomeric cystatin C, stabilized against domain swapping by an int

258 atients had lower levels of cardiotrophin-1, cystatin C, syndecan-4, and N terminal-probrain natriure

259 ciated with mortality when assessed by serum cystatin C than by creatinine.

260 inar-specific markers-namely, alpha-amylase, cystatin C, TMEM16A, and NKCC1.

261 , these results suggest that the addition of cystatin C to creatinine to estimate GFR may improve ide

262 Adding the measurement of cystatin C to that of serum creatinine to determine the

263 Adding cystatin C to the combination of creatinine and ACR meas

264 neutrophil gelatinase-associated lipocalin, cystatin C, trefoil factor 3, tissue inhibitor of metall

265 L68Q) that express the human L68Q variant of cystatin C under the control of the mouse cystatin C pro

266 down-regulated in cell homogenates following cystatin C uptake.

267 hereditary cystatin C amyloid angiopathy, a cystatin C variant is deposited in arterial walls and ca

268 Cystatin C warrants further investigation as a more mean

269 99 to -0.28); the equivalent association for cystatin C was -0.60 kg (95% CI, -0.94 to -0.25) and for

270 ne eGFR was 54+/-20 mL/min per 1.73 m2, mean cystatin C was 11.2 (7.7-16.2) mg/L, and median plasma N

271 Concurrent serum cystatin C was assayed in banked serum samples.

272 Baseline cystatin C was associated with higher carotid intima-med

273 Log cystatin C was directly associated with PASP (adjusted b

274 In contrast, the cysteine protease inhibitor cystatin C was expressed only in tubules.

275 ysis adjusted for age, sex, and comorbidity, cystatin C was near-linearly associated with increased m

276 A causal effect of cystatin C was not detected for any individual component

277 Although mRNA expression of cystatin C was stable, its secretion, which was inhibite

278 legumain inhibitors, cystatin C, E/M, and F, cystatin C was the one mainly produced.

279 A secreted factor, identified as cystatin C, was found to be responsible for this effect.

280 ge glomerular filtration rate estimated from cystatin C well matched follow-up chronic kidney disease

281 mated glomerular filtration rate (eGFR), and cystatin C were assessed in 562 patients with heart fail

282 ardized measurements of serum creatinine and cystatin C were available.

283 in (hsCRP), interleukin (IL)-6, D-dimer, and cystatin C were compared in 494 HIV-infected individuals

284 ng; urinary albumin-to-creatinine ratio; and cystatin C were evaluated at study baseline.

285 Levels of cystatin C were higher in the Tg2576 conditioned medium

286 Several variants of cystatin C were identified and quantified, while none we

287 kidney disease and when both creatinine and cystatin C were used to calculate the eGFR.

288 L9G,V10G)-, (R8G,L9G,V10G,W106G)-, and W106G-cystatin C) were internalized to a very low extent compa

289 binding protein, urinary interleukin-18, and cystatin C) were measured in 1,635 unselected emergency

290 NT-proBNP and IL-6 (but not cystatin C) were more strongly associated with the outco

291 n factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before TAVR and in 100 sex-mat

292 eded in a number of assays, such as that for cystatin C, where a 1.5-fold increase in concentration m

293 ration equation, the eGFR was estimated from cystatin C with all available samples per participant ex

294 extent comparable with the W106F variant of cystatin C with optimal uptake properties and resulting

295 Reductions in cystatin C with statin therapy correlate with reductions

296 ed vesicular co-localization of internalized cystatin C with the lysosomal marker proteins cathepsin

297 id not provide evidence for a causal role of cystatin C, with a causal relative risk for CVD of 1.00

298 terminal pro-B-type natriuretic peptide, and cystatin C, with longer QRS interval, with lower heart r

299 utrophil gelatinase-associated lipocalin and cystatin C, with poorer survival.

300 ecreased the internalization and (R24A,R25A)-cystatin C, with substitutions of charged residues not i